🚀 VC round data is live in beta, check it out!
Medmix Valuation Multiples
Discover revenue and EBITDA valuation multiples for Medmix and similar public comparables like Imricor Medical Systems, Perspective Therapeutics, Myriad Genetics, Kamada and more.
Medmix Overview
About Medmix
Medmix AG delivers technologies in high-precision delivery devices and fluid mixing for applications. It is into two business areas Healthcare and Consumer & Industrial. The Healthcare business area is divided into the Dental, Drug Delivery, and Surgery segments. The Consumer & Industrial business area operates through the Industry and Beauty segments. The majority of its revenue is from the Consumer & Industrial segment. In the Industry segment, dispensers, cartridges, and mixers are used in the construction, transportation (automotive, railways, and aerospace), electronics assembly, infrastructure, and DIY industries. Geographically, it operates in Europe the Middle East and Africa, the Americas, and Asia-Pacific.
Founded
2021
HQ
Employees
2.7K
Website
Financials (LTM)
EV
$782M
Medmix Financials
Medmix reported last 12-month revenue of $582M and EBITDA of $117M.
In the same LTM period, Medmix generated $117M in EBITDA and $26M in net income.
Revenue (LTM)
Medmix P&L
In the most recent fiscal year, Medmix reported revenue of $579M and EBITDA of $116M.
Medmix expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $582M | XXX | $579M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $207M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $117M | XXX | $116M | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $26M | XXX | $23M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $225M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Medmix Stock Performance
Medmix has current market cap of $475M, and enterprise value of $782M.
Market Cap Evolution
Medmix's stock price is $11.67.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $782M | $475M | 0.2% | XXX | XXX | XXX | $0.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialMedmix Valuation Multiples
Medmix trades at 1.3x EV/Revenue multiple, and 6.7x EV/EBITDA.
EV / Revenue (LTM)
Medmix Financial Valuation Multiples
As of April 20, 2026, Medmix has market cap of $475M and EV of $782M.
Equity research analysts estimate Medmix's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Medmix has a P/E ratio of 18.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $475M | XXX | $475M | XXX | XXX | XXX |
| EV (current) | $782M | XXX | $782M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 1.4x | XXX | XXX | XXX |
| EV/EBITDA | 6.7x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBIT | 19.3x | XXX | 19.9x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 3.8x | XXX | XXX | XXX |
| P/E | 18.5x | XXX | 20.5x | XXX | XXX | XXX |
| EV/FCF | 27.0x | XXX | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Medmix Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Medmix Margins & Growth Rates
Medmix's revenue in the last 12 month grew by 3%.
Medmix's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Medmix's rule of 40 is 23% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Medmix's rule of X is 27% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Medmix Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 23% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 27% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 30% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Medmix Public Comps
See public comps and valuation multiples for other Industrial Parts and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Medmix | XXX | XXX | XXX | XXX | XXX | XXX |
| Imricor Medical Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Myriad Genetics | XXX | XXX | XXX | XXX | XXX | XXX |
| Kamada | XXX | XXX | XXX | XXX | XXX | XXX |
| Paul Mueller | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Medmix M&A Activity
Medmix acquired XXX companies to date.
Last acquisition by Medmix was on XXXXXXXX, XXXXX. Medmix acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Medmix
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialMedmix Investment Activity
Medmix invested in XXX companies to date.
Medmix made its latest investment on XXXXXXXX, XXXXX. Medmix invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Medmix
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Medmix
| When was Medmix founded? | Medmix was founded in 2021. |
| Where is Medmix headquartered? | Medmix is headquartered in Switzerland. |
| How many employees does Medmix have? | As of today, Medmix has over 2K employees. |
| Is Medmix publicly listed? | Yes, Medmix is a public company listed on SIX Swiss Exchange. |
| What is the stock symbol of Medmix? | Medmix trades under MEDX ticker. |
| When did Medmix go public? | Medmix went public in 2021. |
| Who are competitors of Medmix? | Medmix main competitors are Imricor Medical Systems, Perspective Therapeutics, Myriad Genetics, Kamada. |
| What is the current market cap of Medmix? | Medmix's current market cap is $475M. |
| What is the current revenue of Medmix? | Medmix's last 12 months revenue is $582M. |
| What is the current revenue growth of Medmix? | Medmix revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Medmix? | Current revenue multiple of Medmix is 1.3x. |
| Is Medmix profitable? | Yes, Medmix is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Medmix? | Medmix's last 12 months EBITDA is $117M. |
| What is Medmix's EBITDA margin? | Medmix's last 12 months EBITDA margin is 20%. |
| What is the current EV/EBITDA multiple of Medmix? | Current EBITDA multiple of Medmix is 6.7x. |
| What is the current FCF of Medmix? | Medmix's last 12 months FCF is $29M. |
| What is Medmix's FCF margin? | Medmix's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Medmix? | Current FCF multiple of Medmix is 27.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.